Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 55


Development of Novel antimiRzymes for Targeted Inhibition of miR-21 Expression in Solid Cancer Cells.

Larcher LM, Wang T, Veedu RN.

Molecules. 2019 Jul 7;24(13). pii: E2489. doi: 10.3390/molecules24132489.


Systematic evaluation of 2'-Fluoro modified chimeric antisense oligonucleotide-mediated exon skipping in vitro.

Chen S, Le BT, Chakravarthy M, Kosbar TR, Veedu RN.

Sci Rep. 2019 Apr 15;9(1):6078. doi: 10.1038/s41598-019-42523-0.


Antisense Oligonucleotides Targeting Angiogenic Factors as Potential Cancer Therapeutics.

Le BT, Raguraman P, Kosbar TR, Fletcher S, Wilton SD, Veedu RN.

Mol Ther Nucleic Acids. 2019 Mar 1;14:142-157. doi: 10.1016/j.omtn.2018.11.007. Epub 2018 Nov 20. Review.


Three decades of nucleic acid aptamer technologies: Lessons learned, progress and opportunities on aptamer development.

Wang T, Chen C, Larcher LM, Barrero RA, Veedu RN.

Biotechnol Adv. 2019 Jan - Feb;37(1):28-50. doi: 10.1016/j.biotechadv.2018.11.001. Epub 2018 Nov 5. Review.


Radiolabeling of Nucleic Acid Aptamers for Highly Sensitive Disease-Specific Molecular Imaging.

Hassanzadeh L, Chen S, Veedu RN.

Pharmaceuticals (Basel). 2018 Oct 15;11(4). pii: E106. doi: 10.3390/ph11040106. Review.


Systematic Screening of Commonly Used Commercial Transfection Reagents towards Efficient Transfection of Single-Stranded Oligonucleotides.

Wang T, Larcher LM, Ma L, Veedu RN.

Molecules. 2018 Oct 8;23(10). pii: E2564. doi: 10.3390/molecules23102564.


Development of DNA aptamers targeting low-molecular-weight amyloid-β peptide aggregates in vitro.

Chakravarthy M, AlShamaileh H, Huang H, Tannenberg RK, Chen S, Worrall S, Dodd PR, Veedu RN.

Chem Commun (Camb). 2018 May 1;54(36):4593-4596. doi: 10.1039/c8cc02256a.


Self-assembling asymmetric peptide-dendrimer micelles - a platform for effective and versatile in vitro nucleic acid delivery.

Kokil GR, Veedu RN, Le BT, Ramm GA, Parekh HS.

Sci Rep. 2018 Mar 19;8(1):4832. doi: 10.1038/s41598-018-22902-9.


Rational Design of Short Locked Nucleic Acid-Modified 2'-O-Methyl Antisense Oligonucleotides for Efficient Exon-Skipping In Vitro.

Le BT, Adams AM, Fletcher S, Wilton SD, Veedu RN.

Mol Ther Nucleic Acids. 2017 Dec 15;9:155-161. doi: 10.1016/j.omtn.2017.09.002. Epub 2017 Sep 12.


Development of Cell-Specific Aptamers: Recent Advances and Insight into the Selection Procedures.

Rahimizadeh K, AlShamaileh H, Fratini M, Chakravarthy M, Stephen M, Shigdar S, Veedu RN.

Molecules. 2017 Nov 27;22(12). pii: E2070. doi: 10.3390/molecules22122070. Review.


Nucleic Acid-Based Theranostics for Tackling Alzheimer's Disease.

Chakravarthy M, Chen S, Dodd PR, Veedu RN.

Theranostics. 2017 Sep 5;7(16):3933-3947. doi: 10.7150/thno.21529. eCollection 2017. Review.


Construction of a Bivalent Thrombin Binding Aptamer and Its Antidote with Improved Properties.

Hughes QW, Le BT, Gilmore G, Baker RI, Veedu RN.

Molecules. 2017 Oct 19;22(10). pii: E1770. doi: 10.3390/molecules22101770.


Next-Generation Nucleic Acid Aptamers with Two-Base-Modified Nucleotides Have Improved Binding Affinity and Potency.

AlShamaileh H, Veedu RN.

Chembiochem. 2017 Aug 17;18(16):1565-1567. doi: 10.1002/cbic.201700276. Epub 2017 Jun 26.


Novel Chemically-modified DNAzyme targeting Integrin alpha-4 RNA transcript as a potential molecule to reduce inflammation in multiple sclerosis.

Chakravarthy M, Aung-Htut MT, Le BT, Veedu RN.

Sci Rep. 2017 May 9;7(1):1613. doi: 10.1038/s41598-017-01559-w.


Development of an Efficient G-Quadruplex-Stabilised Thrombin-Binding Aptamer Containing a Three-Carbon Spacer Molecule.

Aaldering LJ, Poongavanam V, Langkjaer N, Murugan NA, Jørgensen PT, Wengel J, Veedu RN.

Chembiochem. 2017 Apr 18;18(8):755-763. doi: 10.1002/cbic.201600654. Epub 2017 Mar 15.


In vitro evolution of chemically-modified nucleic acid aptamers: Pros and cons, and comprehensive selection strategies.

Lipi F, Chen S, Chakravarthy M, Rakesh S, Veedu RN.

RNA Biol. 2016 Dec;13(12):1232-1245. Epub 2016 Oct 7. Review.


Targeting VEGF with LNA-stabilized G-rich oligonucleotide for efficient breast cancer inhibition.

Edwards SL, Poongavanam V, Kanwar JR, Roy K, Hillman KM, Prasad N, Leth-Larsen R, Petersen M, Marušič M, Plavec J, Wengel J, Veedu RN.

Chem Commun (Camb). 2015 Jun 11;51(46):9499-502. doi: 10.1039/c5cc02756j. Epub 2015 May 13.


Type 2 diabetes mellitus: limitations of conventional therapies and intervention with nucleic acid-based therapeutics.

Kokil GR, Veedu RN, Ramm GA, Prins JB, Parekh HS.

Chem Rev. 2015 Jun 10;115(11):4719-43. doi: 10.1021/cr5002832. Epub 2015 Apr 28. Review. No abstract available.


Supplemental Content

Loading ...
Support Center